## CLAIMS

1. An agent for treating or preventing a cerebrovascular disorder, wherein the agent comprises an HGF gene.

5

- 2. The agent of claim 1, wherein the cerebrovascular disorder is a cerebral infarction.
- 3. The agent of claim 1 or 2, wherein the agent is in the form of a tablet, pill, sugar-coated tablet, capsule, liquid, gel, ointment, syrup, slurry, or suspension.
- 4. The agent of any one of claims 1 to 3, wherein the agent is used to transfer a gene into a cell by a method employing a viral envelope vector, internal type liposome, electrostatic type liposome, HVJ-liposome, or improved HVJ-liposome, a receptor-mediated gene transfer method, a method for transferring a nucleic acid molecule along with a carrier into a cell by using a particle gun, a direct introduction method using a naked-DNA, or an introduction method using a cationic polymer.
  - 5. The agent of any one of claims 1 to 3, wherein the agent is used to transfer a gene into a cell by employing an HVJ-envelope.
- 25 6. A method for treating or preventing a cerebrovascular disorder, wherein the method comprises the step of introducing an HGF gene into a mammal.
- 7. The method of claim 6, wherein the cerebrovascular disorder is a cerebral infarction.
  - 8. The method of claim 6 or 7, wherein the method comprises the step of introducing an HGF gene into a mammal two to three times by employing an HVJ-envelope.

35

9. Use of an HGF gene to produce an agent for treating or preventing

a cerebrovascular disorder.

10. The use of the HGF gene of claim 9, wherein the cerebrovascular disorder is a cerebral infarction.

5